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Abstract
Pulmonary drug delivery is currently the focus of accelerated research and development because of the potential to
produce maximum therapeutic benefit to patients by directly targeting drug to the site of pathology in the lungs.
Among the available delivery options, the dry powder inhaler (DPI) is the preferred device for the treatment of an
increasingly diverse range of diseases. However, because drug delivery from a DPI involves a complex interaction
between the device and the patient, the engineering development of this medical technology is proving to be a
great challenge. Development of DPI systems that target the delivery of fine drug particles to the deeper airways in
the lungs using a combination of improved drug formulations and enhanced delivery device technologies means
that each of these factors contributes to overall performance of the aerosol system. There are a large range of devices
that are currently available, or under development, for clinical use, however no individual device shows superior
clinical efficacy. A major concern that is very relevant in day-to-day clinical practice is the inter- and intra-patient
variability of the drug dosage delivered to the deep lungs from the inhalation devices, where the extent
of variability depends on the drug formulation, the device design, and the patient’s inhalation profile.
This variability may result in under-dosing of drug to the patient and potential loss of pharmacological
efficacy. This article reviews recent advances in capsule-based DPI technology and the introduction of the
‘disposable’ DPI device.
Keywords: Asthma, Chronic obstructive pulmonary disease, Drug delivery, Dry powder inhalers, Technology
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Background
The benefits of inhaled therapy for the treatment of
asthma and chronic obstructive pulmonary disease
(COPD) have been recognised for many years. In compari-
son with oral or parenteral formulations, minute but
therapeutic doses of drug are delivered topically into the
airways where the active drug exerts its beneficial effects
locally within the lungs. Unwanted systemic effects are
minimised because the medication acts with maximum
pulmonary specificity together with a rapid onset of ac-
tion. As a result, aerosol formulations of bronchodilators
and corticosteroids are the mainstay of modern treatment
for asthma and COPD [1, 2]. Central to the success of
inhaled treatment has been the availability of efficient
aerosol delivery systems or inhalers.
Pressurised metered-dose inhalers (pMDIs) and dry
powder inhalers (DPIs) are the devices most commonly
used for drug delivery in the treatment of asthma and
COPD. The pMDIs, which first became available in the
mid-1950s, are globally the most widely-prescribed in-
haler devices because they are cheap and use consistent
technology to deliver a variety of medications. However,
pMDIs do have some disadvantages in terms of
effectiveness and usability. Most patients cannot use
pMDIs correctly, even after repeated tuition [3], because
pMDIs require good coordination between inhaler
actuation and patient inspiration to ensure correct inha-
lation and deposition of drug in the lungs [4]. Misuse of
pMDIs is frequent and associated with poorer asthma
control in inhaled corticosteroid-treated asthma patients
[5]. In contrast, because DPIs are actuated and driven by
a patient’s inspiratory flow, they do not require propel-
lants to generate the aerosol, nor coordination of inhaler
actuation with inhalation [6]. However, a forceful and
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deep inhalation through the DPI is needed to de-aggregate
the powder formulation into respirable particles as effi-
ciently as possible in order to ensure that drug is delivered
to the lungs [7, 8]. Although most patients are capable of
generating enough flow to operate a DPI efficiently [9, 10],
the need to inhale forcefully, and therefore generate a
sufficient inspiratory flow, remains a problem for young
children and patients with severe airflow limitation. For
this reason, DPIs are not recommended for use in children
under the age of 5 years. Less well known is that DPIs
should also not be used in patients with compromised re-
spiratory function who often do not have the inspiratory
effort needed to ensure effective drug delivery from DPIs.
At the same time that DPIs were introduced, there was an
environmental concern that the chlorofluorocarbon (CFC)
propellants used in pMDIs were contributing to irrepa-
rable damage to the ozone layer in the atmosphere. The
pharmaceutical industry was, therefore, committed to the
development of non-CFC propellants for use in pMDIs,
and also to the development of DPIs that did not require
any propellant at all [6–8]. Reformulation of pMDIs to
change to hydrofluoroalkane propellants was challenging
but resulted in drug formulations with favorable safety
and tolerability profiles, although the need to reformulate
inhaled corticosteroids (ICS) and long-acting beta-
adrenergic bronchodilators (LABA) for use in pMDIs
presented particular technical difficulties, especially
regarding the achievement of dose-content uniformity.
Another important distinction between DPIs and pMDIs,
particularly those delivering standard coarse (>2 μm) aero-
sol particles, is that with the latter inhalers no more than
20% of the emitted dose reaches the lungs [6–8].
Conversely, DPIs have been associated with a pulmonary
drug deposition rate that can be as high as 40% of the
administered dose, provided patients use optimally-
controlled inhalation flows through the device, otherwise
lung deposition can be as low as ~15%. The high speed of
the aerosol droplets exiting from a pMDI, or the high
inhalation flows needed from some DPIs may result in
marked droplet deposition in the oropharynx (between
50% and 80% of the administered dose), with subsequent
potential for local adverse drug effects such as oral can-
didiasis and dysphonia, and systemic drug absorption after
swallowing [11]. These issues may be resolved somewhat
through the use of spacer devices in conjunction with the
pMDI or the use of DPIs that require slower inhalation
flows [12]. Bronchoconstriction is an uncommon adverse
reaction following use of pMDIs, and is thought to be
caused by excipients, such as oleic acid, possibly in
combination with the propellant [13], whereas DPIs
contain no propellants or preservatives [14].
The main types of DPI systems are shown in Fig. 1. The
single-unit dose inhaler requires the patient to load a
single hard gelatine capsule containing the powder
formulation into the device before each use (Fig. 1a). This
is a very common type of DPI device currently available.
Figure 1b shows a device containing a pre-metered
amount of a single dose that is discarded after use. Multi-
unit devices deliver individual doses from pre-metered re-
placeable blisters, disks, dimples or tubes (Fig. 1c).
Multiple-dose reservoir inhalers (Fig. 1d) contain a bulk
amount of drug powder in the device with a built in
mechanism to meter a single dose and individual doses
are delivered with each actuation. The multi-unit inhalers
Fig. 1 a-d types of dry powder inhalers and corresponding mechanisms for drug deagglomeration and dispersion. Modified from [8]
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(Fig. 1c) are likely to ensure greater dosage control and
chemical stability of the formulation than multiple dose
types (Fig. 1d); however, the former are more expensive
than the latter.
This brief review focuses on recent improvements in
capsule-based DPI technology and on the recent
introduction of capsule-based disposable inhalers.
Capsule-based DPI technology
Although therapeutic application of capsule-based DPIs
began in the middle of last century with the introduction
of the Aerohaler® for the delivery of antibiotics,[15] the
Spinhaler®, introduced at the end of the 1960s, was the
first DPI containing a powder formulation of bronchoac-
tive drugs in a gelatine capsule, which the patient loaded
into the device prior to use. Since then, DPI systems
have constantly evolved in technology and performance,
a trend that still continues [16].
DPI formulations may either be fine powder drug (par-
ticle size <5 μm) blended with larger carrier particles
(generally lactose) to prevent aggregation and increase
powder flow prior to aerosolization, or it may consist of
drug alone (Fig. 2). In all cases, the powder formulations
travel along the airways to deposit in the targeted areas
of the lung, and then dissolve to exert their pharmaco-
dynamic effect or are absorbed to reach systemic targets.
A drug particle size between 1 and 5 μm is needed for
entry into the deep lung by inhalation and particles of
1–2 μm are most suitable for reaching the small airways
(an important anatomical target for the treatment of
asthma and COPD) and alveolar epithelium (an
important target for systemic delivery/absorption of
orally inhaled products) [17].
The role of the technology in DPI devices is to disperse
the powder mixtures into a respirable fine drug particle
fraction by aerodynamic means. The aerodynamic beha-
vior of a DPI is affected by its design, dimension, and
geometry of the functional engineered device parts, such
as the air-inlet/air-outlet, inhaler resistance, mechanisms
of disaggregating powder mixtures (helicoids, sieves,
cyclone channel) and emptying the dose (Venturi-effect,
centrifugal forces, spinning/twisting). For instance, the air-
inlet size has been shown to have a significant impact on
powder dispersion at different inhalation flow rates by
varying the inlet jet flow turbulences and particle inter-
action velocity [18, 19]. The performance of the device
can also be modified by the resistance to airflow, which
has a direct impact on the peak inspiratory flow (PIF),
acceleration rate, inhaled volume to reach PIF, and total
inhalation time [20].
Furthermore, the shape of the drug particle affects DPI
performance. For instance, elongated particles have been
found to achieve higher fine particle fractions released due
to the unstable particle interactions [21]. Finally, and
probably most importantly, interactions between drug and
carrier particles are crucial with respect to the formulation
Fig. 2 Schematic diagram of dry powder inhaler formulations and dispensing powder mechanisms. a Drug-only formulation (drug agglomerates);
b Carrier-based formulation. See text for further details. Modified from [7, 8]
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performance [22]. Irregular surface structures prevent the
particles from close interaction and ease the separation
from each other upon aerodynamic stress.
Particle engineering using additional excipients, such
as amino acids or sugar derivatives, in the drug-carrier
formulations is another field of research to design the
particle and surface characteristics for use in carrier-
based and carrier-free DPI systems [23]. An example of
this is a recently launched DPI formulation delivering
tobramycin for the treatment of cystic fibrosis. This DPI
formulation is characterized by microspheres of a sub-
micron oil-in-water emulsion of tobramycin, distearoyl
phosphatidylcholine and calcium chloride that is manu-
factured by spray drying to form porous particles of
amorphous tobramycin. This novel capsule-based DPI
formulation has been shown to achieve lung deposition
of 34.2% of the delivered dose [24].
The performance of DPI formulations is also related to
the characteristics of the primary packaging, from which
the formulation is released upon activation in the device.
Due to the ease and availability of capsule filling, DPIs
use hard gelatin or hypromellose capsules as pre-
metered monodose unit systems [25]. Capsule activation
is achieved by shear-force opening, needle-piercing, or
cutting of the capsules. Key characteristics of the capsule
are the moisture content and water activity, puncturing
performance in the device and powder retention [25].
The moisture content of the capsule depends on the
environmental moisture level to which it equilibrates.
Hypromellose capsules have lower the total water
content than gelatin capsules (about 6% versus 14%
water at 50% relative humidity [RH]); even so, the water
activity between the shells remains similar when equili-
brated to the same RH storage conditions. Puncturing
by needles is the most frequent mechanism used by DPI
systems to release drug powder from the capsules [25].
Generally, the number of needles used for puncturing
ranges from 1 to 8 and puncturing can occur from the
top of the capsule or from the side. Although the
puncturing behavior under normal storage conditions
has been found to be good for both types of capsules,
hypromellose capsules exhibit high performance upon
puncturing even under very dry conditions without any
fractions or particles from the shell [25].
The quantity of drug powder retention in the capsule de-
pends on the interplay between the surface properties of
the capsule shell, the characteristics of the interactive pow-
der mixture, and the functioning of the device. With a
given formulation and device, powder retention can be
modified by changing the surface characteristics of the cap-
sule to achieve the optimal performance target [25]. This
performance target might well be the emitted fine particle
fraction, which is also based on the de-agglomeration effect
of the capsule on the powder mixture [25].
All currently available passive DPI systems rely solely on
the inspiratory force of the patient to disperse drug
powders. When the patient activates the DPI and inhales,
airflow through the device creates shear and turbulence;
air is introduced into the powder bed which is fluidized
and enters the patient’s airways. Thus, the drug particles,
separated from the carrier particles, are carried deep into
the lungs, while the larger carrier particles impact in the
oropharynx and are cleared. As a result, deposition into
the lungs is determined by the patient’s variable inspira-
tory airflow [8]. However, each DPI system has a specific
airflow resistance that is due to the physical design of the
device; this means that a threshold inspiratory force is
required to achieve the correct flow rate to aerosolize,
deagglomerate, and disperse the powder formulation in
order to achieve an effective therapeutic response. It is the
physical design of the DPI that establishes its specific re-
sistance to airflow (measured as the square root of the
pressure drop across the device divided by the flow rate
through the device), with current designs having specific
resistance values ranging from about 0.05 to 0.3 cmH2O/
L/min [26]. To produce a fine powder aerosol with in-
creased delivery to the lung, a DPI characterized as having
a low resistance requires an inspiratory flow of >90 L/min,
a medium-resistance DPI requires 50-60 L/min, and a
high-resistance DPI requires <50 L/min [26]. Of note,
DPIs with high intrinsic resistance, and hence increased
pressure drop across the device, tend to produce a greater
lung deposition than those with low intrinsic
resistance;[26] however, the clinical significance of this is
unknown.
Breezhaler®: an example of recent capsule-based DPI
The Breezhaler device (Fig. 3) is a single-dose DPI based
on the Aerolizer technology with design changes
intended to improve device handling and appearance.
The Breezhaler is used to deliver drug from capsules
containing the long-acting beta-adrenergic bronchodila-
tor indacaterol maleate and the long-acting muscarinic
antagonist glycopyrronium. The device has been de-
signed to have lower internal airflow resistance (0.15
cmH2O/L/min) than that of other capsule–based DPIs
such as the HandiHaler device (0.22 cmH2O/L/min).
Due to its low intrinsic internal resistance it requires
high inspiratory flow rates (100 and 117 L/min) to ob-
tain a mean pressure drop of 4 kPa within the device
[27]. However, Pavkov et al. [28] and Singh et al. [29]
have shown that COPD patients are able to generate a
peak inspiratory airflow of approximately 90 L/min
through the Breezhaler device, overcoming a pressure
drop of approximately 3 kPa. Although performance of
DPIs are usually compared at 4 kPa pressure drop [26],
studies in COPD patients demonstrated consistent dose
delivery from Breezhaler using flow rates between 50
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and 100 L/min [28, 30] corresponding to a pressure drop
less than 4 kPa. DPIs with low resistance tend to be
more accepted by patients than those with high resist-
ance [31]. In elderly patients, the ability to generate suf-
ficient inspiratory flow through a DPI is compromised,
irrespective of the presence of airway obstruction, as
shown by Janssens et al.[32] who demonstrated that 30,
20 and 12.5% of an elderly population were not able to
reach the minimum peak inspiratory flow of 45 L/min
when using the Turbuhaler, Diskus and Aerolizer DPIs,
respectively. Keeping this in mind, the choice of a lower
resistance DPI, which is relatively insensitive to changes
in peak inspiratory flow at lower flow levels, would def-
initely benefit the patients. The recent ERS/ISAM task-
force on inhalers [33] recommends patients “to inhale
forcefully from the beginning of inspiration, as deeply as
possible, and to continue to inhale for as long as
possible”. This is because, with a DPI, inhalation should
be forceful enough to disperse the micronized drug from
the lactose-based carrier into a fine particle dose. How-
ever, it is not the absolute inspiratory flow that deter-
mines the fine particle dose from an inhaler, rather it is
the turbulent energy obtained from the relationship be-
tween patient’s inhalation and inhaler device resistance.
High air velocities within the inhaler are required for
effective dispersion rather than high airflow through the
inhaler. The higher the airflow, the higher the powder
dispersion generating a fine particulate, even if such a
high airflow leads to a higher impaction losses in the
proximal airways and, as a result, to a lower dose reach-
ing peripheral airways [27, 34]. On the other hand, a
lower airflow contributes to deeper lung deposition of
the powdered drug, even if a too low airflow (such as
that occurring in patients with the worst disease sever-
ity) can limit deposition by affecting powder disaggrega-
tion and dispersion [27, 34]. Furthermore, when using a
single-dose DPI, such as the Breezhaler, it is also
recommended that patients are instructed to perform
two separate inhalations for each dose [35].
Ease of use and the presence of reliable feedback is con-
sidered by the majority of patients as the most important
features of an inhaler. Patients are in general not assured
that they have taken the full dose correctly with most in-
halation devices and want ease of device use to increase
their acceptance of the device. Healthcare practitioners
emphasize an increase in patient satisfaction because this
potentially increases adherence. To properly operate the
Breezhaler device, patients must load the device by
inserting the capsule of powder into a chamber [35]. After
closing the lid, the capsule is perforated with needles fixed
to pressure buttons; the patient then inhales through the
device, which causes the capsule to rotate within the de-
vice chamber, and this creates a distinctive ‘whirring’ noise
as the capsule spins. Furthermore, patients can see that
they have inhaled all the powder because the capsule is
clear. It is clear when the device is empty and needs to be
refilled. Thus, the Breezhaler device has three potential
feedback mechanisms that give patients an indication that
the full medication dose has been delivered: (a) the device
gives off a ‘whirring noise’ as the capsule spins each time a
patient inhales (providing positive auditory feedback that
the medication is being released from the capsule); (b) the
medication formulation contains lactose, a small amount
of which stays in the patient’s mouth during inhalation
and most patients can taste it; (c) the transparent capsule
will be visibly empty or have only residual traces of
powder after successful inhalation, giving visual feedback
to the patient that the drug has been released [35].
Limitations of capsule-based DPI
Handling-related limitations
Capsule-based DPI requires that single doses are indi-
vidually loaded into the inhaler immediately before use:
this is inconvenient for some patients and does not allow
direct dose counting. The device then needs to be
primed by breaking the capsule, and then, depending on
the patient’s breathing profile, the inhalation process
Fig. 3 The Breezhaler capsule-based dry powder inhaler
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must be continued or repeated until the capsule is
emptied: this may result in under-dosing and high dose
variability. In addition, the sequence of steps required to
properly load the device may not be easy for children or
elderly patients with diminished dexterity. It has been
shown that patients were more confident of the medica-
tion being taken correctly when using the Breezhaler,
and found it more comfortable and simpler to use
compared with the Handihaler [36]; however, the
methodology used to investigate preference for and
satisfaction with a particular inhaler was not validated,
and preference was assessed over a limited time frame.
Technical limitations
It has been shown that the air inlet size and grid structure
of the Aerolizer capsule-based DPI were found to impact
significantly on aerosolization of the carrier-based powder
[37]. More specifically, the powder contained in the cap-
sule needs to be released through the pierced holes at each
end of the capsule during aerosolization. The centrifugal
force generated by the spinning capsule will eject the pow-
der through the capsule holes. When the air flow in-
creases, the capsule rotation speed will increase
significantly,[37] which increases the centrifugal force
hence facilitating the powder exit. As shown with the
Aerolizer, capsule retention has an impact on the fine par-
ticle fraction (FPF) and, more importantly, affects the dose
delivered to patients. In addition, the FPF is higher when
the airflow rate is increased [26]. Thus, at a flow rate
<30 L/min, greater variations in drug retained in the cap-
sules can be observed compared with higher flow rates.
Disposable capsule-based DPI
In inhalation medicine, from an economic perspective, the
trend of the past two decades indisputably has been the
introduction of a large number of generic devices for ad-
ministration of ICS and beta2-agonists for the treatment of
asthma and COPD [38]. In many countries, this develop-
ment and the pressure on healthcare budgets have resulted
in a significant switch from branded to generic medications
and devices. The chronic nature of these asthma and
COPD requires a lifetime of treatment, with a high fre-
quency of drug administration and, therefore, high costs. In
addition, many new applications of inhaled therapy (e.g.
vaccination, rescue medication, enzymes, peptides) may re-
quire inhaler specifications that cannot be achieved using
classic inhaler technology and for several of these applica-
tions, disposable inhaler versions maybe preferred. By de-
sign, capsule-based DPIs seem most suitable as disposables
and can also be developed as single-use devices. Pharma-
ceutical companies using these devices have to adjust their
formulation to the performance of the inhaler, which often
includes the incorporation of new excipients, up to
substantial amounts, and the use of complex preparation
techniques. An example is the PulmoSphere® formulation
for the antibiotic tobramycin in the former Turbospin
capsule-based inhaler, now referred to as Podhaler for
tobramycin. However, disposable DPIs used in these set-
tings still need to be simple and inexpensive, but also highly
effective and reproducible. Many recipients in, for instance,
vaccination programs will be inhaler-naive and providers
may not always be well-trained. Simple design will therefore
facilitate correct use, preferably almost by intuition.
Conclusions
In the last decade, we have observed an increasing interest
in DPI technology in response to the need for alternatives
to ozone-depleting and greenhouse gas-propelled inhaler
devices, and new approaches to the delivery of potent drugs
of biological origin. The characteristics and dynamic inte-
raction between fine drug particles and carrier particles, as
well as the interaction between particles and inhaler charac-
teristics, have now been elucidated [39]. The future deve-
lopment of DPI devices will have to focus on simplicity of
use, reliability, consistency, suitability for a large range of
products and doses, feedback mechanisms to the patients,
and last but not least, cost effectiveness. For pulmonary
drug delivery, the device–patient interface has been shown
to be of critical importance because patients vary in their
ability to use inhalation products, but also they differ in the
level of education required for appropriate use. Although
existing DPIs are efficient devices for delivering drugs to
the lung, there is substantial room for improvements
without losing the cost-effectiveness advantages. As a
greater understanding of powdered drug properties and
their influence on performance is obtained, it will be
possible to adopt sophisticated technological approaches to
solve the problems associated with efficient drug delivery to
achieve local and systemic pharmacologic effect.
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